Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 87 | 2024 | 935 | 11.770 |
Why?
|
Polymorphism, Single Nucleotide | 77 | 2023 | 767 | 6.250 |
Why?
|
Vitamin D | 16 | 2023 | 196 | 4.720 |
Why?
|
Genetic Predisposition to Disease | 60 | 2023 | 628 | 4.460 |
Why?
|
Vitamin D Deficiency | 10 | 2023 | 105 | 4.280 |
Why?
|
Genome-Wide Association Study | 38 | 2023 | 333 | 3.250 |
Why?
|
Genetic Variation | 34 | 2020 | 387 | 2.520 |
Why?
|
Male | 164 | 2024 | 20025 | 2.380 |
Why?
|
Skin Pigmentation | 10 | 2021 | 23 | 2.290 |
Why?
|
Humans | 221 | 2024 | 37093 | 2.190 |
Why?
|
Prostate | 12 | 2023 | 154 | 2.190 |
Why?
|
Middle Aged | 105 | 2024 | 10129 | 2.160 |
Why?
|
Aged | 87 | 2024 | 6741 | 2.090 |
Why?
|
Genetic Loci | 13 | 2021 | 90 | 2.010 |
Why?
|
Genotype | 51 | 2021 | 730 | 1.770 |
Why?
|
Case-Control Studies | 46 | 2022 | 1130 | 1.740 |
Why?
|
Health Status Disparities | 6 | 2024 | 642 | 1.710 |
Why?
|
Genetics, Population | 18 | 2015 | 100 | 1.700 |
Why?
|
Chromosomes, Human, Pair 8 | 8 | 2016 | 27 | 1.540 |
Why?
|
Gene Frequency | 31 | 2021 | 195 | 1.490 |
Why?
|
Genome, Human | 13 | 2024 | 135 | 1.460 |
Why?
|
Prostate-Specific Antigen | 16 | 2024 | 118 | 1.430 |
Why?
|
Alleles | 19 | 2021 | 321 | 1.390 |
Why?
|
Adult | 69 | 2022 | 11712 | 1.280 |
Why?
|
Breast Neoplasms | 10 | 2021 | 1502 | 1.260 |
Why?
|
Risk Factors | 40 | 2024 | 3562 | 1.230 |
Why?
|
Healthcare Disparities | 5 | 2024 | 494 | 1.210 |
Why?
|
Polymorphism, Genetic | 14 | 2016 | 191 | 1.150 |
Why?
|
Prostatectomy | 8 | 2021 | 63 | 1.100 |
Why?
|
Chromosome Mapping | 17 | 2018 | 188 | 1.100 |
Why?
|
Haplotypes | 21 | 2018 | 182 | 1.070 |
Why?
|
Melanins | 4 | 2021 | 36 | 1.010 |
Why?
|
Respiratory Function Tests | 1 | 2024 | 55 | 0.930 |
Why?
|
Reference Values | 2 | 2024 | 212 | 0.930 |
Why?
|
Female | 81 | 2022 | 20969 | 0.920 |
Why?
|
Anthropology, Physical | 3 | 2020 | 9 | 0.880 |
Why?
|
Linkage Disequilibrium | 19 | 2017 | 85 | 0.860 |
Why?
|
United States | 35 | 2024 | 4223 | 0.850 |
Why?
|
Genetic Markers | 21 | 2013 | 142 | 0.840 |
Why?
|
Body Mass Index | 6 | 2017 | 854 | 0.840 |
Why?
|
Lung | 4 | 2024 | 446 | 0.830 |
Why?
|
DNA, Mitochondrial | 5 | 2015 | 175 | 0.790 |
Why?
|
Clinical Trials as Topic | 3 | 2021 | 204 | 0.770 |
Why?
|
Receptors, Calcitriol | 5 | 2023 | 69 | 0.720 |
Why?
|
Aged, 80 and over | 23 | 2019 | 2379 | 0.700 |
Why?
|
Lung Neoplasms | 6 | 2023 | 358 | 0.700 |
Why?
|
Promoter Regions, Genetic | 8 | 2012 | 515 | 0.680 |
Why?
|
Warfarin | 6 | 2017 | 64 | 0.680 |
Why?
|
Colorectal Neoplasms | 7 | 2019 | 441 | 0.670 |
Why?
|
Biopsy | 7 | 2023 | 164 | 0.650 |
Why?
|
Genomics | 4 | 2024 | 223 | 0.630 |
Why?
|
Anemia, Sickle Cell | 5 | 2021 | 183 | 0.620 |
Why?
|
Carcinoma | 2 | 2011 | 96 | 0.620 |
Why?
|
Anticoagulants | 6 | 2017 | 102 | 0.590 |
Why?
|
Intercellular Signaling Peptides and Proteins | 6 | 2014 | 98 | 0.580 |
Why?
|
Papillomavirus Vaccines | 1 | 2019 | 151 | 0.570 |
Why?
|
Prognosis | 13 | 2020 | 739 | 0.550 |
Why?
|
Models, Genetic | 13 | 2015 | 172 | 0.550 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2019 | 864 | 0.540 |
Why?
|
Calcium, Dietary | 1 | 2017 | 85 | 0.540 |
Why?
|
Health Education | 1 | 2019 | 338 | 0.530 |
Why?
|
Neoplasm Staging | 7 | 2017 | 275 | 0.530 |
Why?
|
Y Chromosome | 4 | 2001 | 53 | 0.530 |
Why?
|
Incidence | 9 | 2024 | 922 | 0.530 |
Why?
|
Zinc | 1 | 2016 | 128 | 0.520 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2019 | 277 | 0.520 |
Why?
|
Pharmacogenetics | 4 | 2017 | 49 | 0.500 |
Why?
|
Risk Assessment | 10 | 2023 | 753 | 0.500 |
Why?
|
Papillomavirus Infections | 1 | 2019 | 336 | 0.500 |
Why?
|
Phylogeny | 5 | 2012 | 644 | 0.490 |
Why?
|
Chromosomes, Human, Y | 2 | 2012 | 15 | 0.490 |
Why?
|
Germ-Line Mutation | 3 | 2022 | 57 | 0.490 |
Why?
|
Genetic Testing | 4 | 2020 | 75 | 0.490 |
Why?
|
Dietary Supplements | 1 | 2016 | 208 | 0.480 |
Why?
|
Cohort Studies | 18 | 2021 | 1492 | 0.480 |
Why?
|
Multiple Myeloma | 3 | 2020 | 39 | 0.460 |
Why?
|
Socioeconomic Factors | 5 | 2024 | 1067 | 0.460 |
Why?
|
Africa, Western | 10 | 2020 | 18 | 0.450 |
Why?
|
Cell Line, Tumor | 2 | 2019 | 2231 | 0.440 |
Why?
|
Interleukin-16 | 1 | 2012 | 5 | 0.430 |
Why?
|
Body Height | 3 | 2021 | 53 | 0.410 |
Why?
|
Early Detection of Cancer | 3 | 2024 | 336 | 0.410 |
Why?
|
Logistic Models | 9 | 2016 | 923 | 0.400 |
Why?
|
Cross-Sectional Studies | 6 | 2022 | 2721 | 0.390 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2011 | 9 | 0.390 |
Why?
|
DNA Methylation | 5 | 2019 | 325 | 0.390 |
Why?
|
Mutation | 11 | 2021 | 1095 | 0.380 |
Why?
|
Retrospective Studies | 9 | 2021 | 2026 | 0.380 |
Why?
|
Allelic Imbalance | 1 | 2010 | 4 | 0.370 |
Why?
|
Genes, myc | 1 | 2010 | 29 | 0.370 |
Why?
|
Duffy Blood-Group System | 2 | 2021 | 4 | 0.370 |
Why?
|
District of Columbia | 3 | 2020 | 71 | 0.370 |
Why?
|
Genetic Association Studies | 7 | 2017 | 114 | 0.370 |
Why?
|
Gene Dosage | 1 | 2010 | 75 | 0.360 |
Why?
|
Head and Neck Neoplasms | 1 | 2011 | 78 | 0.360 |
Why?
|
Biomedical Research | 4 | 2022 | 400 | 0.350 |
Why?
|
Receptors, Cell Surface | 2 | 2021 | 144 | 0.340 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2021 | 213 | 0.340 |
Why?
|
Africa | 8 | 2021 | 76 | 0.330 |
Why?
|
Odds Ratio | 6 | 2021 | 534 | 0.330 |
Why?
|
Smoking | 6 | 2015 | 940 | 0.330 |
Why?
|
Chicago | 5 | 2020 | 30 | 0.330 |
Why?
|
Endoribonucleases | 1 | 2008 | 23 | 0.330 |
Why?
|
Risk | 7 | 2019 | 267 | 0.330 |
Why?
|
Cadherins | 3 | 2014 | 90 | 0.320 |
Why?
|
Europe | 8 | 2021 | 101 | 0.320 |
Why?
|
Arylamine N-Acetyltransferase | 1 | 2007 | 27 | 0.310 |
Why?
|
Membrane Transport Proteins | 3 | 2009 | 95 | 0.310 |
Why?
|
Receptors, Dopamine D2 | 2 | 2013 | 73 | 0.310 |
Why?
|
Cytochrome P-450 Enzyme System | 2 | 2012 | 92 | 0.300 |
Why?
|
Mixed Function Oxygenases | 2 | 2011 | 34 | 0.300 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2007 | 59 | 0.300 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 1 | 2007 | 23 | 0.300 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2021 | 807 | 0.300 |
Why?
|
Neoplasm Proteins | 2 | 2008 | 213 | 0.300 |
Why?
|
Receptor, EphB2 | 2 | 2011 | 5 | 0.290 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2007 | 70 | 0.290 |
Why?
|
Multivariate Analysis | 4 | 2016 | 583 | 0.290 |
Why?
|
Membrane Proteins | 4 | 2012 | 517 | 0.290 |
Why?
|
Codon, Nonsense | 2 | 2007 | 21 | 0.280 |
Why?
|
Caribbean Region | 3 | 2013 | 69 | 0.280 |
Why?
|
Selection, Genetic | 4 | 2014 | 54 | 0.280 |
Why?
|
Multigene Family | 1 | 2006 | 106 | 0.270 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2006 | 152 | 0.270 |
Why?
|
Cell Adhesion Molecules | 1 | 2006 | 75 | 0.270 |
Why?
|
Algorithms | 6 | 2015 | 465 | 0.270 |
Why?
|
Vitamin D-Binding Protein | 1 | 2005 | 4 | 0.270 |
Why?
|
Asthma | 4 | 2017 | 380 | 0.260 |
Why?
|
Diabetes Mellitus, Type 2 | 6 | 2015 | 643 | 0.260 |
Why?
|
Multifactorial Inheritance | 4 | 2023 | 19 | 0.260 |
Why?
|
Genetics | 1 | 2004 | 9 | 0.250 |
Why?
|
Quantitative Trait, Heritable | 3 | 2014 | 26 | 0.250 |
Why?
|
Melanoma | 2 | 2016 | 96 | 0.240 |
Why?
|
Young Adult | 11 | 2021 | 4268 | 0.240 |
Why?
|
Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 41 | 0.230 |
Why?
|
Isoenzymes | 1 | 2004 | 161 | 0.220 |
Why?
|
Nigeria | 6 | 2012 | 86 | 0.220 |
Why?
|
DNA, Neoplasm | 3 | 2010 | 92 | 0.220 |
Why?
|
Receptors, Corticotropin | 1 | 2003 | 4 | 0.220 |
Why?
|
Principal Component Analysis | 5 | 2019 | 89 | 0.220 |
Why?
|
Germ Cells | 2 | 2022 | 73 | 0.220 |
Why?
|
Calcifediol | 1 | 2023 | 15 | 0.220 |
Why?
|
Carrier Proteins | 3 | 2012 | 305 | 0.220 |
Why?
|
Monophenol Monooxygenase | 1 | 2003 | 14 | 0.220 |
Why?
|
Models, Statistical | 4 | 2014 | 180 | 0.220 |
Why?
|
Endonucleases | 2 | 2021 | 20 | 0.220 |
Why?
|
Base Sequence | 8 | 2011 | 997 | 0.220 |
Why?
|
Androgens | 1 | 2023 | 89 | 0.210 |
Why?
|
Phenotype | 8 | 2017 | 689 | 0.210 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 2 | 2014 | 52 | 0.210 |
Why?
|
Inheritance Patterns | 2 | 2016 | 9 | 0.210 |
Why?
|
National Cancer Institute (U.S.) | 3 | 2017 | 25 | 0.210 |
Why?
|
DNA Primers | 4 | 2010 | 286 | 0.210 |
Why?
|
Regression Analysis | 5 | 2016 | 455 | 0.210 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2021 | 178 | 0.210 |
Why?
|
Evolution, Molecular | 4 | 2014 | 268 | 0.200 |
Why?
|
Apoptosis Regulatory Proteins | 2 | 2014 | 147 | 0.200 |
Why?
|
Trinucleotide Repeats | 1 | 2001 | 4 | 0.200 |
Why?
|
Hypertension | 2 | 2020 | 796 | 0.200 |
Why?
|
Steroid 17-alpha-Hydroxylase | 1 | 2001 | 10 | 0.200 |
Why?
|
Adolescent | 10 | 2019 | 5363 | 0.200 |
Why?
|
Indians, North American | 5 | 2007 | 159 | 0.200 |
Why?
|
Heart Failure | 2 | 2015 | 235 | 0.200 |
Why?
|
Interleukin-18 | 1 | 2021 | 15 | 0.190 |
Why?
|
Tachycardia, Ventricular | 1 | 2021 | 12 | 0.190 |
Why?
|
Disease Susceptibility | 2 | 2019 | 97 | 0.190 |
Why?
|
Social Class | 2 | 2020 | 247 | 0.190 |
Why?
|
Geography | 3 | 2012 | 96 | 0.190 |
Why?
|
Sex Factors | 5 | 2015 | 898 | 0.190 |
Why?
|
Ohio | 1 | 2020 | 14 | 0.190 |
Why?
|
Oklahoma | 1 | 2020 | 29 | 0.190 |
Why?
|
Medicine | 1 | 2021 | 33 | 0.190 |
Why?
|
Chi-Square Distribution | 2 | 2016 | 225 | 0.190 |
Why?
|
Diabetes Mellitus | 1 | 2006 | 485 | 0.190 |
Why?
|
Receptors, Androgen | 1 | 2001 | 126 | 0.180 |
Why?
|
New York | 1 | 2020 | 71 | 0.180 |
Why?
|
Diagnostic Tests, Routine | 1 | 2020 | 47 | 0.180 |
Why?
|
Chromosomes, Human, Pair 5 | 2 | 2018 | 10 | 0.180 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2019 | 31 | 0.180 |
Why?
|
HIV Infections | 1 | 2014 | 2303 | 0.180 |
Why?
|
Cities | 1 | 2020 | 63 | 0.180 |
Why?
|
Cardiomyopathies | 1 | 2021 | 56 | 0.180 |
Why?
|
Air Pollutants | 1 | 2021 | 94 | 0.180 |
Why?
|
Alcoholism | 2 | 2003 | 240 | 0.180 |
Why?
|
Hair Preparations | 1 | 2019 | 2 | 0.180 |
Why?
|
Pedigree | 8 | 2011 | 79 | 0.180 |
Why?
|
Follow-Up Studies | 3 | 2019 | 974 | 0.180 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 88 | 0.180 |
Why?
|
Jamaica | 2 | 2012 | 11 | 0.170 |
Why?
|
Proteomics | 1 | 2022 | 325 | 0.170 |
Why?
|
Quality of Life | 1 | 2023 | 481 | 0.170 |
Why?
|
Social Identification | 1 | 2019 | 58 | 0.170 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 20 | 0.170 |
Why?
|
Isoantibodies | 1 | 2018 | 7 | 0.170 |
Why?
|
Ki-67 Antigen | 1 | 2019 | 33 | 0.170 |
Why?
|
Personality | 1 | 1999 | 42 | 0.170 |
Why?
|
Point Mutation | 1 | 1999 | 93 | 0.160 |
Why?
|
Mass Screening | 4 | 2024 | 462 | 0.160 |
Why?
|
Selectins | 1 | 2018 | 2 | 0.160 |
Why?
|
Chemokines | 1 | 2019 | 97 | 0.160 |
Why?
|
Receptor, Notch1 | 1 | 2018 | 17 | 0.160 |
Why?
|
Hemoglobins | 2 | 2015 | 107 | 0.160 |
Why?
|
Microsatellite Repeats | 4 | 2007 | 59 | 0.160 |
Why?
|
GTPase-Activating Proteins | 1 | 2018 | 29 | 0.160 |
Why?
|
Receptor, erbB-2 | 1 | 2019 | 133 | 0.160 |
Why?
|
Oncogene Proteins | 1 | 2017 | 21 | 0.150 |
Why?
|
Interferon Regulatory Factors | 1 | 2017 | 17 | 0.150 |
Why?
|
Health Priorities | 1 | 2017 | 19 | 0.150 |
Why?
|
Health Planning | 1 | 2017 | 16 | 0.150 |
Why?
|
Hela Cells | 1 | 2019 | 366 | 0.150 |
Why?
|
Prostatic Hyperplasia | 2 | 2016 | 34 | 0.150 |
Why?
|
Agouti Signaling Protein | 3 | 2006 | 3 | 0.150 |
Why?
|
Prospective Studies | 4 | 2021 | 1378 | 0.150 |
Why?
|
DNA Repair | 2 | 2010 | 188 | 0.150 |
Why?
|
Trust | 1 | 2019 | 133 | 0.150 |
Why?
|
Microfilament Proteins | 1 | 2017 | 69 | 0.150 |
Why?
|
Receptors, Metabotropic Glutamate | 2 | 2014 | 28 | 0.150 |
Why?
|
Skin Neoplasms | 2 | 2016 | 159 | 0.150 |
Why?
|
Treatment Outcome | 5 | 2022 | 1369 | 0.150 |
Why?
|
Respiratory Tract Diseases | 1 | 2017 | 23 | 0.150 |
Why?
|
Serine Endopeptidases | 1 | 2017 | 38 | 0.150 |
Why?
|
Survival Analysis | 5 | 2019 | 325 | 0.150 |
Why?
|
Antihypertensive Agents | 1 | 2020 | 284 | 0.150 |
Why?
|
Eosinophilia | 1 | 2017 | 18 | 0.150 |
Why?
|
Calcitriol | 1 | 2017 | 31 | 0.140 |
Why?
|
Antipsychotic Agents | 2 | 2014 | 68 | 0.140 |
Why?
|
Obesity | 2 | 2017 | 1067 | 0.140 |
Why?
|
Urologic Surgical Procedures | 1 | 2016 | 5 | 0.140 |
Why?
|
Population | 3 | 2009 | 10 | 0.140 |
Why?
|
Organ Size | 1 | 2016 | 157 | 0.140 |
Why?
|
Chromosomes, Human | 2 | 2014 | 35 | 0.140 |
Why?
|
Nutrition Assessment | 1 | 2016 | 79 | 0.140 |
Why?
|
Procollagen | 1 | 2015 | 4 | 0.140 |
Why?
|
Minority Groups | 2 | 2021 | 596 | 0.140 |
Why?
|
Carcinoma, Renal Cell | 1 | 2016 | 36 | 0.140 |
Why?
|
Forecasting | 2 | 2017 | 128 | 0.130 |
Why?
|
Venous Thromboembolism | 1 | 2016 | 13 | 0.130 |
Why?
|
DNA | 3 | 2015 | 574 | 0.130 |
Why?
|
Kidney Neoplasms | 1 | 2016 | 68 | 0.130 |
Why?
|
Ultraviolet Rays | 1 | 2016 | 117 | 0.130 |
Why?
|
Adiposity | 1 | 2017 | 154 | 0.130 |
Why?
|
Apolipoprotein B-100 | 1 | 2015 | 7 | 0.130 |
Why?
|
Uruguay | 1 | 2015 | 2 | 0.130 |
Why?
|
Calcium | 2 | 2016 | 480 | 0.130 |
Why?
|
Naltrexone | 1 | 2015 | 38 | 0.130 |
Why?
|
Drug Dosage Calculations | 1 | 2015 | 3 | 0.130 |
Why?
|
Sequence Analysis, DNA | 2 | 2014 | 474 | 0.130 |
Why?
|
Cause of Death | 1 | 2015 | 156 | 0.130 |
Why?
|
Finland | 3 | 1999 | 13 | 0.130 |
Why?
|
Receptors, Scavenger | 1 | 2014 | 15 | 0.130 |
Why?
|
Proteins | 1 | 2017 | 369 | 0.120 |
Why?
|
Genealogy and Heraldry | 1 | 2014 | 5 | 0.120 |
Why?
|
Radiotherapy | 1 | 2014 | 18 | 0.120 |
Why?
|
Amphetamines | 1 | 2014 | 5 | 0.120 |
Why?
|
Phenprocoumon | 1 | 2014 | 1 | 0.120 |
Why?
|
Acenocoumarol | 1 | 2014 | 2 | 0.120 |
Why?
|
Transcription Factors | 2 | 2017 | 681 | 0.120 |
Why?
|
Bone Morphogenetic Protein 4 | 1 | 2014 | 8 | 0.120 |
Why?
|
Dopamine Plasma Membrane Transport Proteins | 1 | 2014 | 50 | 0.120 |
Why?
|
Molecular Sequence Data | 7 | 2011 | 1568 | 0.120 |
Why?
|
Mitogen-Activated Protein Kinase 8 | 1 | 2014 | 12 | 0.120 |
Why?
|
Gene Expression Regulation, Enzymologic | 2 | 2014 | 168 | 0.120 |
Why?
|
Nerve Tissue Proteins | 3 | 2012 | 360 | 0.120 |
Why?
|
Glutarates | 1 | 2013 | 2 | 0.120 |
Why?
|
Memory, Short-Term | 1 | 2014 | 49 | 0.120 |
Why?
|
Ocular Motility Disorders | 1 | 2013 | 1 | 0.120 |
Why?
|
Schizophrenia | 1 | 2014 | 76 | 0.120 |
Why?
|
Human Genome Project | 2 | 2012 | 7 | 0.120 |
Why?
|
Kidney | 1 | 2016 | 337 | 0.120 |
Why?
|
Epigenesis, Genetic | 1 | 2016 | 219 | 0.120 |
Why?
|
Peptide Fragments | 1 | 2015 | 308 | 0.110 |
Why?
|
Proto-Oncogene Proteins c-myc | 1 | 2013 | 54 | 0.110 |
Why?
|
Receptors, AMPA | 1 | 2013 | 56 | 0.110 |
Why?
|
Analysis of Variance | 3 | 2015 | 550 | 0.110 |
Why?
|
Kidney Diseases | 1 | 2015 | 167 | 0.110 |
Why?
|
Ghana | 3 | 2022 | 32 | 0.110 |
Why?
|
Quantitative Trait Loci | 4 | 2016 | 77 | 0.110 |
Why?
|
Hypertension, Pulmonary | 1 | 2014 | 75 | 0.110 |
Why?
|
Bayes Theorem | 3 | 2008 | 94 | 0.110 |
Why?
|
NAD(P)H Dehydrogenase (Quinone) | 1 | 2012 | 16 | 0.110 |
Why?
|
Adenocarcinoma | 2 | 2018 | 251 | 0.110 |
Why?
|
Aldosterone | 1 | 2013 | 66 | 0.110 |
Why?
|
Psychotic Disorders | 1 | 2013 | 55 | 0.110 |
Why?
|
Genetic Research | 2 | 2010 | 9 | 0.110 |
Why?
|
Proportional Hazards Models | 2 | 2015 | 441 | 0.110 |
Why?
|
Overweight | 1 | 2015 | 247 | 0.110 |
Why?
|
Health Services Accessibility | 1 | 2017 | 560 | 0.110 |
Why?
|
Data Interpretation, Statistical | 1 | 2012 | 111 | 0.100 |
Why?
|
Atrial Fibrillation | 1 | 2013 | 101 | 0.100 |
Why?
|
Cameroon | 1 | 2012 | 38 | 0.100 |
Why?
|
Fathers | 1 | 2012 | 33 | 0.100 |
Why?
|
Crossing Over, Genetic | 1 | 2011 | 5 | 0.100 |
Why?
|
Tobacco Use Disorder | 1 | 2015 | 237 | 0.100 |
Why?
|
Seasons | 1 | 2012 | 112 | 0.100 |
Why?
|
Cognition Disorders | 1 | 2013 | 233 | 0.100 |
Why?
|
Acute Lung Injury | 1 | 2011 | 6 | 0.100 |
Why?
|
Ephrin-B2 | 1 | 2011 | 1 | 0.100 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2011 | 10 | 0.100 |
Why?
|
Thyroid Hormones | 1 | 2011 | 27 | 0.100 |
Why?
|
Iodide Peroxidase | 1 | 2011 | 35 | 0.100 |
Why?
|
Crohn Disease | 1 | 2012 | 63 | 0.100 |
Why?
|
Animals | 10 | 2023 | 15081 | 0.100 |
Why?
|
Hypopharyngeal Neoplasms | 1 | 2011 | 1 | 0.100 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2011 | 9 | 0.100 |
Why?
|
Mice | 6 | 2023 | 5913 | 0.100 |
Why?
|
Age Factors | 3 | 2015 | 1033 | 0.100 |
Why?
|
Early Diagnosis | 1 | 2011 | 64 | 0.100 |
Why?
|
Receptors, Lysosphingolipid | 1 | 2010 | 4 | 0.090 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2014 | 282 | 0.090 |
Why?
|
Indians, South American | 2 | 2007 | 8 | 0.090 |
Why?
|
Introns | 2 | 2011 | 75 | 0.090 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2010 | 53 | 0.090 |
Why?
|
Internationality | 2 | 2021 | 32 | 0.090 |
Why?
|
Sepsis | 1 | 2011 | 80 | 0.090 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2010 | 9 | 0.090 |
Why?
|
Membrane Glycoproteins | 2 | 2015 | 211 | 0.090 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2015 | 1039 | 0.090 |
Why?
|
Dinucleotide Repeats | 1 | 2009 | 2 | 0.090 |
Why?
|
Chromosome Aberrations | 1 | 2010 | 60 | 0.090 |
Why?
|
Antigens, Neoplasm | 2 | 2007 | 59 | 0.090 |
Why?
|
Homozygote | 1 | 2009 | 77 | 0.090 |
Why?
|
Computer Simulation | 4 | 2014 | 362 | 0.090 |
Why?
|
History, 21st Century | 1 | 2009 | 81 | 0.090 |
Why?
|
Glutathione Transferase | 1 | 2009 | 88 | 0.090 |
Why?
|
Antiporters | 2 | 2006 | 10 | 0.090 |
Why?
|
Vestibular Aqueduct | 1 | 2009 | 1 | 0.090 |
Why?
|
Survival Rate | 3 | 2020 | 311 | 0.090 |
Why?
|
Hearing Loss | 1 | 2009 | 15 | 0.080 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2010 | 161 | 0.080 |
Why?
|
Neoplasms | 2 | 2017 | 1103 | 0.080 |
Why?
|
Epidemiologic Studies | 2 | 2005 | 31 | 0.080 |
Why?
|
Fatty Acids | 1 | 2010 | 127 | 0.080 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2023 | 268 | 0.080 |
Why?
|
Smoking Cessation | 1 | 2015 | 517 | 0.080 |
Why?
|
Asia | 2 | 2014 | 75 | 0.080 |
Why?
|
Health Status | 1 | 2012 | 380 | 0.080 |
Why?
|
Population Dynamics | 2 | 2014 | 35 | 0.080 |
Why?
|
Social Environment | 2 | 2010 | 207 | 0.080 |
Why?
|
Stem Cell Factor | 1 | 2007 | 4 | 0.080 |
Why?
|
Orphan Nuclear Receptors | 1 | 2007 | 6 | 0.080 |
Why?
|
Smegmamorpha | 1 | 2007 | 24 | 0.080 |
Why?
|
ROC Curve | 2 | 2020 | 138 | 0.080 |
Why?
|
Deafness | 1 | 2007 | 7 | 0.080 |
Why?
|
beta-N-Acetylhexosaminidases | 1 | 2007 | 4 | 0.080 |
Why?
|
Health | 1 | 2007 | 30 | 0.080 |
Why?
|
Histone Acetyltransferases | 1 | 2007 | 19 | 0.070 |
Why?
|
West Indies | 2 | 2007 | 13 | 0.070 |
Why?
|
TCF Transcription Factors | 1 | 2007 | 15 | 0.070 |
Why?
|
Patient Selection | 3 | 2010 | 164 | 0.070 |
Why?
|
Neoplasm Invasiveness | 2 | 2021 | 251 | 0.070 |
Why?
|
Anxiety | 1 | 2014 | 754 | 0.070 |
Why?
|
History | 1 | 2006 | 1 | 0.070 |
Why?
|
Apoptosis | 4 | 2022 | 1398 | 0.070 |
Why?
|
Economics | 1 | 2006 | 5 | 0.070 |
Why?
|
Chromosome Inversion | 1 | 2006 | 8 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2006 | 14 | 0.070 |
Why?
|
Leukemia, Myeloid | 1 | 2006 | 9 | 0.070 |
Why?
|
Translocation, Genetic | 1 | 2006 | 42 | 0.070 |
Why?
|
Regulatory Elements, Transcriptional | 1 | 2006 | 11 | 0.070 |
Why?
|
Agouti-Related Protein | 1 | 2006 | 12 | 0.070 |
Why?
|
Open Reading Frames | 1 | 2006 | 77 | 0.070 |
Why?
|
Sudden Infant Death | 1 | 2006 | 6 | 0.070 |
Why?
|
Body Fat Distribution | 1 | 2006 | 24 | 0.070 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2006 | 56 | 0.070 |
Why?
|
Epidemiologic Methods | 2 | 2008 | 49 | 0.070 |
Why?
|
Exons | 1 | 2006 | 88 | 0.070 |
Why?
|
Longitudinal Studies | 2 | 2020 | 885 | 0.070 |
Why?
|
Sequence Deletion | 1 | 2006 | 87 | 0.070 |
Why?
|
Receptors, Estrogen | 2 | 2019 | 156 | 0.070 |
Why?
|
Muscle Proteins | 1 | 2006 | 51 | 0.070 |
Why?
|
Cardiovascular Diseases | 2 | 2014 | 664 | 0.070 |
Why?
|
Sodium Channels | 1 | 2006 | 67 | 0.070 |
Why?
|
Genetics, Medical | 1 | 2005 | 6 | 0.070 |
Why?
|
5' Untranslated Regions | 1 | 2005 | 18 | 0.070 |
Why?
|
Culture | 1 | 2006 | 173 | 0.060 |
Why?
|
Immunohistochemistry | 3 | 2019 | 893 | 0.060 |
Why?
|
Zebrafish Proteins | 1 | 2005 | 47 | 0.060 |
Why?
|
Disease Models, Animal | 3 | 2023 | 1371 | 0.060 |
Why?
|
Polymerase Chain Reaction | 2 | 2009 | 448 | 0.060 |
Why?
|
Blood Pressure | 2 | 2020 | 646 | 0.060 |
Why?
|
Gene Expression | 2 | 2021 | 674 | 0.060 |
Why?
|
Arrhythmias, Cardiac | 2 | 2021 | 36 | 0.060 |
Why?
|
Spain | 3 | 2011 | 36 | 0.060 |
Why?
|
Names | 1 | 2004 | 2 | 0.060 |
Why?
|
Calpain | 1 | 2005 | 35 | 0.060 |
Why?
|
Databases as Topic | 1 | 2004 | 20 | 0.060 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 2 | 2017 | 9 | 0.060 |
Why?
|
National Human Genome Research Institute (U.S.) | 1 | 2024 | 2 | 0.060 |
Why?
|
Transcription, Genetic | 1 | 2007 | 578 | 0.060 |
Why?
|
Zebrafish | 1 | 2005 | 128 | 0.060 |
Why?
|
Genetic Diseases, Inborn | 1 | 2004 | 12 | 0.060 |
Why?
|
Blood Glucose | 1 | 2006 | 353 | 0.060 |
Why?
|
Ataxia | 1 | 2003 | 9 | 0.060 |
Why?
|
Dystonia | 1 | 2003 | 4 | 0.060 |
Why?
|
Iron Overload | 1 | 2003 | 8 | 0.060 |
Why?
|
Aftercare | 1 | 2023 | 19 | 0.060 |
Why?
|
Body Weight | 1 | 2006 | 434 | 0.060 |
Why?
|
Alcohol Dehydrogenase | 1 | 2003 | 10 | 0.060 |
Why?
|
Predictive Value of Tests | 2 | 2020 | 400 | 0.060 |
Why?
|
Cation Transport Proteins | 1 | 2003 | 34 | 0.060 |
Why?
|
Aldehyde Dehydrogenase | 1 | 2003 | 17 | 0.060 |
Why?
|
Cyclooxygenase 2 | 1 | 2004 | 104 | 0.060 |
Why?
|
Receptors, Melanocortin | 1 | 2003 | 3 | 0.060 |
Why?
|
Patient Discharge | 1 | 2023 | 93 | 0.060 |
Why?
|
Practice Guidelines as Topic | 1 | 2024 | 191 | 0.060 |
Why?
|
Cell Line | 3 | 2015 | 1354 | 0.060 |
Why?
|
Biology | 1 | 2022 | 16 | 0.050 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2023 | 58 | 0.050 |
Why?
|
Coculture Techniques | 1 | 2023 | 101 | 0.050 |
Why?
|
Epithelium | 1 | 2022 | 79 | 0.050 |
Why?
|
Hydrogels | 1 | 2023 | 37 | 0.050 |
Why?
|
Models, Biological | 1 | 2006 | 677 | 0.050 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2002 | 24 | 0.050 |
Why?
|
Sensitivity and Specificity | 2 | 2020 | 562 | 0.050 |
Why?
|
Receptors, Dopamine D4 | 1 | 2002 | 14 | 0.050 |
Why?
|
Testosterone | 1 | 2023 | 193 | 0.050 |
Why?
|
Chromatin | 1 | 2023 | 169 | 0.050 |
Why?
|
Minisatellite Repeats | 1 | 2001 | 18 | 0.050 |
Why?
|
Orchiectomy | 1 | 2021 | 35 | 0.050 |
Why?
|
Acute Disease | 2 | 2015 | 147 | 0.050 |
Why?
|
North America | 1 | 2001 | 67 | 0.050 |
Why?
|
Emigration and Immigration | 3 | 2007 | 82 | 0.050 |
Why?
|
Prednisone | 1 | 2021 | 27 | 0.050 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2001 | 11 | 0.050 |
Why?
|
Poverty Areas | 1 | 2021 | 41 | 0.050 |
Why?
|
Interleukin-6 | 1 | 2022 | 153 | 0.050 |
Why?
|
Antigens, Surface | 1 | 2001 | 43 | 0.050 |
Why?
|
Beauty | 1 | 2020 | 1 | 0.050 |
Why?
|
Disease-Free Survival | 1 | 2021 | 113 | 0.050 |
Why?
|
Unnecessary Procedures | 1 | 2020 | 9 | 0.050 |
Why?
|
RNA Splicing | 1 | 2021 | 40 | 0.050 |
Why?
|
Homeodomain Proteins | 1 | 2022 | 132 | 0.050 |
Why?
|
Particulate Matter | 1 | 2021 | 51 | 0.050 |
Why?
|
Rural Population | 1 | 2003 | 294 | 0.050 |
Why?
|
Men | 1 | 2020 | 19 | 0.050 |
Why?
|
Chromatography, High Pressure Liquid | 2 | 2017 | 421 | 0.050 |
Why?
|
Tongue Neoplasms | 1 | 2000 | 11 | 0.050 |
Why?
|
Transcriptional Elongation Factors | 1 | 2020 | 6 | 0.050 |
Why?
|
Africa South of the Sahara | 1 | 2019 | 46 | 0.040 |
Why?
|
California | 1 | 2021 | 476 | 0.040 |
Why?
|
Glutamine | 2 | 2013 | 40 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 182 | 0.040 |
Why?
|
Indians, Central American | 1 | 2019 | 3 | 0.040 |
Why?
|
Mouth Neoplasms | 1 | 2000 | 71 | 0.040 |
Why?
|
Tissue Array Analysis | 1 | 2019 | 67 | 0.040 |
Why?
|
Chromosomes, Human, Pair 2 | 1 | 2018 | 8 | 0.040 |
Why?
|
Receptors, Progesterone | 1 | 2019 | 81 | 0.040 |
Why?
|
Receptors, Adrenergic, alpha-1 | 1 | 2018 | 14 | 0.040 |
Why?
|
Exploratory Behavior | 1 | 1999 | 75 | 0.040 |
Why?
|
Focus Groups | 1 | 2020 | 348 | 0.040 |
Why?
|
Amino Acid Sequence | 3 | 2007 | 1180 | 0.040 |
Why?
|
Avoidance Learning | 1 | 1999 | 62 | 0.040 |
Why?
|
Transfection | 2 | 2010 | 523 | 0.040 |
Why?
|
Reward | 1 | 1999 | 79 | 0.040 |
Why?
|
Databases, Factual | 1 | 2019 | 291 | 0.040 |
Why?
|
Residence Characteristics | 1 | 2021 | 322 | 0.040 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2014 | 190 | 0.040 |
Why?
|
Chromosomes, Human, Pair 13 | 1 | 2017 | 11 | 0.040 |
Why?
|
Medical Oncology | 1 | 2017 | 30 | 0.040 |
Why?
|
Cluster Analysis | 2 | 2009 | 195 | 0.040 |
Why?
|
Pulmonary Medicine | 1 | 2017 | 2 | 0.040 |
Why?
|
Insulin Receptor Substrate Proteins | 1 | 2017 | 20 | 0.040 |
Why?
|
Waist-Hip Ratio | 1 | 2017 | 34 | 0.040 |
Why?
|
Chromosomes, Human, Pair 22 | 1 | 2017 | 39 | 0.040 |
Why?
|
Inflammation | 2 | 2014 | 618 | 0.040 |
Why?
|
Sex Characteristics | 1 | 1999 | 230 | 0.040 |
Why?
|
Sputum | 1 | 2017 | 17 | 0.040 |
Why?
|
Societies, Medical | 1 | 2017 | 66 | 0.040 |
Why?
|
Leukocyte Count | 1 | 2017 | 77 | 0.040 |
Why?
|
Transmembrane Activator and CAML Interactor Protein | 1 | 2016 | 1 | 0.040 |
Why?
|
Immunoglobulin E | 1 | 2017 | 55 | 0.040 |
Why?
|
Anthropometry | 1 | 2017 | 97 | 0.040 |
Why?
|
Cytoskeletal Proteins | 1 | 2017 | 105 | 0.040 |
Why?
|
Adrenal Cortex Hormones | 1 | 2017 | 53 | 0.040 |
Why?
|
Forced Expiratory Volume | 1 | 2017 | 70 | 0.040 |
Why?
|
Atlases as Topic | 1 | 2016 | 5 | 0.030 |
Why?
|
Mexico | 2 | 2007 | 240 | 0.030 |
Why?
|
Chromosomes, Human, Pair 20 | 1 | 2016 | 5 | 0.030 |
Why?
|
Thrombomodulin | 1 | 2016 | 5 | 0.030 |
Why?
|
Neutrophils | 1 | 2017 | 131 | 0.030 |
Why?
|
Acetylation | 1 | 2016 | 98 | 0.030 |
Why?
|
Glomerular Filtration Rate | 1 | 2016 | 139 | 0.030 |
Why?
|
Lod Score | 2 | 2007 | 9 | 0.030 |
Why?
|
Mexican Americans | 2 | 2009 | 189 | 0.030 |
Why?
|
Hemoglobinuria | 1 | 2015 | 4 | 0.030 |
Why?
|
Circadian Rhythm | 1 | 2018 | 225 | 0.030 |
Why?
|
Health Policy | 1 | 2017 | 165 | 0.030 |
Why?
|
Receptors, Virus | 1 | 2015 | 21 | 0.030 |
Why?
|
Heme Oxygenase-1 | 1 | 2015 | 51 | 0.030 |
Why?
|
Apolipoproteins | 1 | 2015 | 22 | 0.030 |
Why?
|
Tandem Mass Spectrometry | 1 | 2017 | 182 | 0.030 |
Why?
|
Kidney Tubules, Proximal | 1 | 2015 | 28 | 0.030 |
Why?
|
Sequence Homology, Amino Acid | 2 | 2007 | 269 | 0.030 |
Why?
|
Lipoproteins, HDL | 1 | 2015 | 46 | 0.030 |
Why?
|
Epistasis, Genetic | 1 | 2014 | 16 | 0.030 |
Why?
|
Leukocytes | 1 | 2015 | 72 | 0.030 |
Why?
|
Triglycerides | 1 | 2015 | 138 | 0.030 |
Why?
|
History, Ancient | 1 | 2014 | 12 | 0.030 |
Why?
|
Needs Assessment | 1 | 2016 | 170 | 0.030 |
Why?
|
Histones | 1 | 2016 | 190 | 0.030 |
Why?
|
Smad7 Protein | 1 | 2014 | 5 | 0.030 |
Why?
|
Linear Models | 1 | 2015 | 275 | 0.030 |
Why?
|
Agriculture | 1 | 2014 | 56 | 0.030 |
Why?
|
Puerto Rico | 1 | 2019 | 1378 | 0.030 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2013 | 8 | 0.030 |
Why?
|
Infant | 2 | 2009 | 1046 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2014 | 108 | 0.030 |
Why?
|
Cell Hypoxia | 1 | 2014 | 58 | 0.030 |
Why?
|
Alcohol Oxidoreductases | 1 | 2013 | 22 | 0.030 |
Why?
|
Nuclear Proteins | 2 | 2008 | 307 | 0.030 |
Why?
|
Markov Chains | 2 | 2004 | 35 | 0.030 |
Why?
|
Repressor Proteins | 1 | 2016 | 249 | 0.030 |
Why?
|
Cholesterol | 1 | 2015 | 205 | 0.030 |
Why?
|
Antigens, CD | 1 | 2014 | 121 | 0.030 |
Why?
|
Child | 2 | 2014 | 3131 | 0.030 |
Why?
|
Gene Expression Regulation | 2 | 2010 | 1015 | 0.030 |
Why?
|
Metabolome | 1 | 2013 | 53 | 0.030 |
Why?
|
Double-Blind Method | 1 | 2014 | 286 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2013 | 173 | 0.030 |
Why?
|
Mitochondrial Proteins | 1 | 2013 | 107 | 0.030 |
Why?
|
Software | 1 | 2014 | 217 | 0.030 |
Why?
|
Chromosomes, Human, Pair 10 | 1 | 2012 | 6 | 0.030 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2012 | 7 | 0.030 |
Why?
|
Receptors, Retinoic Acid | 1 | 2012 | 26 | 0.030 |
Why?
|
Nod2 Signaling Adaptor Protein | 1 | 2012 | 6 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2014 | 234 | 0.030 |
Why?
|
Receptors, Interleukin | 1 | 2012 | 11 | 0.030 |
Why?
|
CpG Islands | 1 | 2012 | 97 | 0.030 |
Why?
|
Proteoglycans | 1 | 2012 | 47 | 0.030 |
Why?
|
Central Nervous System Stimulants | 1 | 2014 | 174 | 0.030 |
Why?
|
Statistics as Topic | 1 | 2012 | 117 | 0.030 |
Why?
|
Research | 2 | 2004 | 163 | 0.030 |
Why?
|
GTP-Binding Proteins | 1 | 2012 | 60 | 0.030 |
Why?
|
North Carolina | 1 | 2011 | 104 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2013 | 409 | 0.020 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2011 | 28 | 0.020 |
Why?
|
Amino Acid Motifs | 1 | 2011 | 91 | 0.020 |
Why?
|
Probability | 1 | 2011 | 78 | 0.020 |
Why?
|
Receptors, Nicotinic | 1 | 2012 | 106 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2016 | 1207 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2014 | 935 | 0.020 |
Why?
|
Critical Illness | 1 | 2011 | 38 | 0.020 |
Why?
|
Fear | 1 | 2014 | 249 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2014 | 357 | 0.020 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2011 | 88 | 0.020 |
Why?
|
Ethics Committees, Research | 1 | 2010 | 10 | 0.020 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2012 | 92 | 0.020 |
Why?
|
Academies and Institutes | 1 | 2010 | 37 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2012 | 194 | 0.020 |
Why?
|
Receptors, Interleukin-10 | 1 | 2010 | 4 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2010 | 149 | 0.020 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2010 | 24 | 0.020 |
Why?
|
Awareness | 1 | 2010 | 65 | 0.020 |
Why?
|
Mitochondria | 1 | 2013 | 487 | 0.020 |
Why?
|
Interleukin-10 | 1 | 2010 | 75 | 0.020 |
Why?
|
Chromosomes, Human, Pair 7 | 1 | 2009 | 6 | 0.020 |
Why?
|
Cultural Characteristics | 1 | 2010 | 125 | 0.020 |
Why?
|
New York City | 1 | 2010 | 220 | 0.020 |
Why?
|
COS Cells | 1 | 2009 | 69 | 0.020 |
Why?
|
Syndrome | 1 | 2009 | 74 | 0.020 |
Why?
|
Dietary Fats | 1 | 2010 | 119 | 0.020 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2010 | 93 | 0.020 |
Why?
|
Americas | 1 | 2009 | 7 | 0.020 |
Why?
|
Xenopus | 1 | 2009 | 48 | 0.020 |
Why?
|
Immunity, Innate | 1 | 2010 | 149 | 0.020 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 1 | 2008 | 4 | 0.020 |
Why?
|
Cotinine | 1 | 2009 | 43 | 0.020 |
Why?
|
DNA Ligases | 1 | 2008 | 13 | 0.020 |
Why?
|
San Francisco | 1 | 2008 | 32 | 0.020 |
Why?
|
Computational Biology | 1 | 2011 | 293 | 0.020 |
Why?
|
Oocytes | 1 | 2009 | 146 | 0.020 |
Why?
|
Melanocytes | 1 | 2007 | 6 | 0.020 |
Why?
|
Gills | 1 | 2007 | 11 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2010 | 610 | 0.020 |
Why?
|
Protein Transport | 1 | 2009 | 302 | 0.020 |
Why?
|
Crosses, Genetic | 1 | 2007 | 48 | 0.020 |
Why?
|
Saliva | 1 | 2009 | 107 | 0.020 |
Why?
|
Genes, Recessive | 1 | 2007 | 7 | 0.020 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2007 | 7 | 0.020 |
Why?
|
Pakistan | 1 | 2007 | 20 | 0.020 |
Why?
|
Regulatory Sequences, Nucleic Acid | 1 | 2007 | 49 | 0.020 |
Why?
|
Hyaluronoglucosaminidase | 1 | 2007 | 20 | 0.020 |
Why?
|
Gene Flow | 1 | 2007 | 14 | 0.020 |
Why?
|
Genome, Mitochondrial | 1 | 2007 | 12 | 0.020 |
Why?
|
Social Problems | 1 | 2007 | 14 | 0.020 |
Why?
|
Attitude to Health | 1 | 2010 | 325 | 0.020 |
Why?
|
Pilot Projects | 1 | 2010 | 661 | 0.020 |
Why?
|
Cell Membrane | 1 | 2009 | 381 | 0.020 |
Why?
|
Chronic Disease | 1 | 2010 | 484 | 0.020 |
Why?
|
Mexiletine | 1 | 2006 | 1 | 0.020 |
Why?
|
Nicotine | 1 | 2009 | 257 | 0.020 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2006 | 12 | 0.020 |
Why?
|
Melanosomes | 1 | 2005 | 3 | 0.020 |
Why?
|
Ion Transport | 1 | 2005 | 17 | 0.020 |
Why?
|
History, 16th Century | 1 | 2005 | 5 | 0.020 |
Why?
|
History, 17th Century | 1 | 2005 | 5 | 0.020 |
Why?
|
Alanine | 1 | 2005 | 30 | 0.020 |
Why?
|
Pigment Epithelium of Eye | 1 | 2005 | 33 | 0.020 |
Why?
|
Threonine | 1 | 2005 | 25 | 0.020 |
Why?
|
Genes | 1 | 2005 | 60 | 0.020 |
Why?
|
Language | 1 | 2007 | 157 | 0.020 |
Why?
|
Latin America | 1 | 2005 | 45 | 0.020 |
Why?
|
Heterozygote | 1 | 2005 | 93 | 0.020 |
Why?
|
Ion Channel Gating | 1 | 2006 | 83 | 0.020 |
Why?
|
Patch-Clamp Techniques | 1 | 2006 | 223 | 0.020 |
Why?
|
Chromosomes, Human, X | 1 | 2005 | 22 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2008 | 539 | 0.020 |
Why?
|
Environment | 1 | 2006 | 138 | 0.020 |
Why?
|
Protein Conformation | 1 | 2006 | 389 | 0.020 |
Why?
|
Child, Preschool | 1 | 2009 | 1418 | 0.020 |
Why?
|
Demography | 1 | 2004 | 175 | 0.010 |
Why?
|
Hematologic Tests | 1 | 2003 | 7 | 0.010 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2003 | 9 | 0.010 |
Why?
|
Lymphatic Metastasis | 1 | 2004 | 65 | 0.010 |
Why?
|
Histidine | 1 | 2003 | 42 | 0.010 |
Why?
|
Age of Onset | 1 | 2004 | 100 | 0.010 |
Why?
|
Family Health | 1 | 2004 | 56 | 0.010 |
Why?
|
Physical Examination | 1 | 2003 | 43 | 0.010 |
Why?
|
Ferritins | 1 | 2003 | 55 | 0.010 |
Why?
|
Monte Carlo Method | 1 | 2003 | 57 | 0.010 |
Why?
|
Mucins | 1 | 2003 | 35 | 0.010 |
Why?
|
Selection Bias | 1 | 2002 | 11 | 0.010 |
Why?
|
Cell Division | 1 | 2003 | 307 | 0.010 |
Why?
|
Iron | 1 | 2003 | 225 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 2003 | 219 | 0.010 |
Why?
|
Decision Making | 1 | 2004 | 203 | 0.010 |
Why?
|
Syntaxin 1 | 1 | 2001 | 2 | 0.010 |
Why?
|
Ethanol | 1 | 2003 | 192 | 0.010 |
Why?
|
South Carolina | 1 | 2001 | 25 | 0.010 |
Why?
|
Methods | 1 | 2000 | 13 | 0.010 |
Why?
|
Colonic Neoplasms | 1 | 2003 | 186 | 0.010 |
Why?
|
Polymorphism, Single-Stranded Conformational | 1 | 2000 | 12 | 0.010 |
Why?
|
Mesocricetus | 1 | 2000 | 54 | 0.010 |
Why?
|
9,10-Dimethyl-1,2-benzanthracene | 1 | 2000 | 29 | 0.010 |
Why?
|
Cricetinae | 1 | 2000 | 238 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2003 | 587 | 0.010 |
Why?
|
Family | 1 | 2000 | 173 | 0.010 |
Why?
|
Carcinogens | 1 | 2000 | 124 | 0.010 |
Why?
|
Health Surveys | 1 | 2001 | 373 | 0.010 |
Why?
|
Research Design | 1 | 2001 | 313 | 0.010 |
Why?
|